Fred E. Cohen - 05 Jan 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Reporting relationship: Director
Issuer ticker: NTLA
Reported as of: 05 Jan 2026
Net transaction value: +$1,402,500
SEC form: 4
Accepted by SEC: 07 Jan 2026, 16:05:06 UTC
Prior SEC filing: 17 Jun 2025
Next SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: /s/ James Basta, attorney-in-fact

Key filing fact

Fred E. Cohen filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 07 Jan 2026.

Key facts

This page summarizes Fred E. Cohen's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Jan 2026, 16:05.

Change

Previous filing in this sequence was filed on 17 Jun 2025.
Current net transaction value: +$1,402,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001339358 Primary reporting owner

Cohen Fred E

Relationship: Director
Address: C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE
Signature: /s/ James Basta, attorney-in-fact
Signature date: 07 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTLA transaction

Common Stock

Purchase

Transaction value: $1,402,500
Shares: +150,000
Change %: +261%
Price: $9.35
Shares after: 207,453
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price.